Literature DB >> 9027947

Classification, etiology, and considerations of outcome in acute liver failure.

R Williams1.   

Abstract

Clinical descriptions of fulminant hepatic failure as originally reported, along with the subgroups of subfulminant and late onset hepatic failure identified later, are considered in relation to the proposed new classification of hyperacute, acute, and subacute liver failure. This reflects different clinical patterns of illness, etiology, and most importantly, prognosis. In addition to the defining state of encephalopathy and other manifestations directly related to the severe derangement in function and structure of the liver, the constellation of clinical symptoms and signs in acute liver failure (ALF) includes, to varying degrees, those of multiorgan failure. The latter develops because of tissue hypoxia from microcirculatory changes consequent on endotoxemia, and activation of macrophages and release of cytokines as a result of secondary bacteria infection due to an early failure of host defenses to infection in ALF. Paracetamol overdose-the commonest cause of acute liver failure in the United Kingdom-is increasing in frequency in other Western countries, but fulminant viral hepatitis is the most frequent etiology worldwide. Marked geographical variations are seen in the frequency with which the viral types A to E are implicated. Whereas hepatitis C is the major cause of ALF in Japan and the Far East, fulminant hepatitis C is seen rarely in America and European countries where most series show that in about one third of cases of presumed viral ALF, no specific agent can be identified. Over the past 10 years, the survival of those with grade 3 to 4 encephalopathy has shown a steady rise as a result of improvements in medical care, quite apart from the introduction and now widespread availability of transplantation for the treatment of this condition. As shown by a number of groups, a variety of different hematologic, biochemical, and clinical features can be used as predictive indices of the likely outcome and in determining the approach to treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9027947     DOI: 10.1055/s-2007-1007247

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  24 in total

Review 1.  Treatment of acute liver failure.

Authors:  K H Boeker
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

2.  Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database.

Authors:  Vincent Lo Re; Kevin Haynes; David Goldberg; Kimberly A Forde; Dena M Carbonari; Kimberly B F Leidl; Sean Hennessy; K Rajender Reddy; Pamala A Pawloski; Gregory W Daniel; T Craig Cheetham; Aarthi Iyer; Kara O Coughlin; Sengwee Toh; Denise M Boudreau; Nandini Selvam; William O Cooper; Mano S Selvan; Jeffrey J VanWormer; Mark I Avigan; Monika Houstoun; Gwen L Zornberg; Judith A Racoosin; Azadeh Shoaibi
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-06-25       Impact factor: 2.890

3.  Altered immune function of monocytes in different stages of patients with acute on chronic liver failure.

Authors:  T Xing; L Li; H Cao; J Huang
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

4.  Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events.

Authors:  Vincent Lo Re; Dena M Carbonari; Kimberly A Forde; David Goldberg; James D Lewis; Kevin Haynes; Kimberly B F Leidl; Rajender K Reddy; Jason Roy; Daohang Sha; Amy R Marks; Jennifer L Schneider; Brian L Strom; Douglas A Corley
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-04-10       Impact factor: 2.890

Review 5.  Etiology and management of fulminant hepatic failure.

Authors:  Javier Vaquero; Andres T Blei
Journal:  Curr Gastroenterol Rep       Date:  2003-02

6.  Elevated resistive index in the hepatic artery as a predictor of fulminant hepatic failure in patients with acute viral hepatitis: a prospective study using Doppler ultrasound.

Authors:  Katsuaki Tanaka; Kazushi Numata; Manabu Morimoto; Kazuhito Shirato; Satoru Saito; Toshio Imada; Shinju Arata; Mitsugi Sugiyama
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

Review 7.  Therapeutic hypothermia for acute liver failure: toward a randomized, controlled trial in patients with advanced hepatic encephalopathy.

Authors:  R Todd Stravitz; William M Lee; Andreas H Kramer; David J Kramer; Linda Hynan; Andres T Blei
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210

8.  Bone marrow-derived immune cells mediate sensitization to liver injury in a myeloid differentiation factor 88-dependent fashion.

Authors:  Istvan Hritz; Arumugam Velayudham; Angela Dolganiuc; Karen Kodys; Pranoti Mandrekar; Evelyn Kurt-Jones; Gyongyi Szabo
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

9.  Liver transplantation().

Authors:  M Rossi; G Mennini; Q Lai; S Ginanni Corradini; F M Drudi; F Pugliese; P B Berloco
Journal:  J Ultrasound       Date:  2007-04-16

10.  Natural course of fulminant hepatic failure: the scenario in Bangladesh and the differences from the west.

Authors:  Shahinul Alam; Golam Azam; Golam Mustafa; Abul Kalam Azad; Izazul Haque; Shakil Gani; Nooruddin Ahmad; Khorshed Alam; Mobin Khan
Journal:  Saudi J Gastroenterol       Date:  2009 Oct-Dec       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.